Pretreatment with a low dose of bacterial endotoxin (lipopolysaccharide, LPS) caused the reduction of cytochrome P450 (CYP) enzymes and inflammatory factors which are capable of protecting the liver from a lethal LPS challenge. However, the effects of LPS pretreatment on the expression of transforming growth factor β1 (TGFβ1) and leptin in thioacetamide (TAA)-induced liver fibrosis remain unknown. In this study, Sprague-Dawley rats were pretreated intraperitoneally with LPS (5 mg/kg body weight) for 24 h, and subsequently treated with TAA (200 mg/kg body weight/ 3 days) for 1 month to examine the effects of LPS on TAA-injured rats. LPS pretreatment was associated with lower granulation and lower (P < 0.05) GOT/GPT than in TAA-injured rats. The LPS-pretreated group had less collagen (Sirius red histochemical staining). Semiquantitative RT-PCR showed that the levels of collagen 3 and TGFβ1 mRNAs were lower (P < 0.05) in the liver of LPS-pretreated rats than in TAA-injured rats. TGFβRI mRNA in the liver of LPS-pretreated rats exceeded (P < 0.05) that in TAA-injured rats. LPS pretreatment reduced the leptin content (Western blot) below that of TAA-injured rats. These results imply that LPS pretreatment (endotoxin tolerance) alleviates the TAA-induced liver fibrosis of rats by reducing TGFβ1 and leptin content.
INTRODUCTION
Lipopolysaccharide (LPS) is a predominant, integral, structural component of the outer membrane of Gramnegative bacteria and is one of the most potent microbial initiators of inflammation. Exposure to a large dose of LPS causes extensive damage to the liver and other organs in humans and rodents. 1 Exposure of liver to small amounts of LPS occurs routinely in numerous ways, including LPS translocation from the intestinal lumen into portal venous blood. 2 Freudenberg and Galanos 3 demonstrated that endotoxin tolerance can protect against a lethal challenge of LPS, suggesting the participation of macrophages to reduce the pathological consequence of LPS. In a previous study, rats were injected with a non-lethal dose of LPS (Escherichia coli O55:B5) followed by a lethal dose of LPS to show that LPS-pretreatment protects against infection and inflammation, and prevents septicemia. 4 LPS pretreatment protects against acetaminophen-and carbon tetrachloride (CCl 4 )-induced liver injury in the short-term. 5, 6 Overproduction of anti-inflammatory cytokines such as interleukin-10 (IL-10) and transforming growth factor β1 (TGFβ1) and secondary down-regulation of LPS receptor(s) at the surface of immune cells protects against the toxicity of some chemicals. 7 Prostaglandins, IL-10 and TGFβ1 are also involved in in vivo endotoxin tolerance. 8 However, the role of endotoxin in cirrhosis of other chemically provoked injury are not completely understood as yet.
Thioacetamide (TAA) is a typical hepatotoxin causing centrolobular necrosis and TAA-induced hepatotoxicity through its S-oxide metabolite (thioacetamide-S-dioxide), which interferes with the movement of RNA from the nucleus to the cytoplasm, causing structural and functional cellular deformation leading to membrane injury. [9] [10] [11] [12] The observed liver enzyme activities (aspartate and alanine aminotransferases [ASP and ALT], glutamate dehydrogenase and threonine deaminase) are lower in the TAA-treated group. Decreases in both transaminases and threonine deaminase are significant. 13 TAA (200 µg/ml)-incubated hepatocyte cells exhibit a 40-62% decline in the marker enzymes glutamyl oxaloacetic transaminase (GOT), glutamyl pyruvic transaminase (GPT) and alkaline phosphatase (AP), and a 50-61% drop in viability and O 2 uptake.
14 TAA causes hepatocyte damage following its metabolism to thioacetamide sulphene and sulphone, via a critical pathway that involves cytochrome P450 (CYP) 2E1-mediated biotransformation. 15, 16 One of the sources of reactive oxygen species (ROS) is the CYP system 17 and the increase of the CYP system promotes hepatic oxidative stress. CCl 4 , cobalt and pyrazole reduce, rather than increase, the total hepatic CYP content. [18] [19] [20] The consequences of liver injury include: (i) the increase in the amount of CYP2E1, CYP2A and CYP3A enzymes; [21] [22] [23] (ii) the production of free radicals causing oxidative stress; (iii) the release of both TGFβ1 and leptin from both activated Kupffer cells (KCs) and hepatic stellate cells (HSCs); and (iv) the accumulation of extracellular matrix (ECM) proteins such as collagen 1 and collagen 3. [24] [25] [26] These changes are responsible for liver fibrosis. TAA exhibited hepatotoxicity-induced liver damage, fibrosis and further cirrhosis. In mice, leptin enhances hepatic fibrosis and induction of α1(I)-procollagen mRNA caused by giving repeated injections of TAA for 4 weeks. 27 Leptin does not cause any fibrotic changes in the liver in ob/ob mice and appears to promote profibrogenic responses in the liver, in part, by up-regulation of TGFβ1. 28 Moreover, leptin can exacerbate the extent of TAAinjured liver fibrosis in mice and may be an important factor in the development of liver fibrosis. 29 Additionally, leptin and its receptors (Ob-Rb) play a pivotal role in profibrogenic responses (α-smooth muscle actin and type I collagen) in the liver of Zucker rats. 30 However, the effects of LPS pretreatment of TAAinduced liver fibrosis on the expression of TGFβ1 and leptin remain unknown. In this study, Sprague-Dawley rats were pretreated intraperitoneally (i.p.) with LPS (5 mg/kg body weight) for 24 h, and then treated with TAA (200 mg/kg body weight/3 days, i.p.) for 1 month to explore the effect of LPS on the TAA-injured rats.
MATERIALS AND METHODS

Animals
Male Sprague-Dawley rats (250-300 g) were obtained from the National Laboratory's Animal Center (Taipei, Taiwan), and were kept in a temperature-controlled environment (22°C). They were fed ad libitum with standard rat chow. The animal experiments were performed according to the Guide for the Care and Use of Laboratory Animals of National Dong-Hwa University. Rats were randomly assigned to TAA-, LPS plus TAA, and placebotreated groups (n = 5, in each group). Liver fibrosis in rats was induced by intraperitoneal (i.p.) injection of thioacetamide (TAA, 200 mg/kg body weight, every 3 days for 30 days) as described elsewhere. 31 Animals in the LPS plus TAA group were given one dose of LPS (5 mg/kg body weight, i.p.) at 24 h before TAA was administered. The control group received the vehicle (normal saline solution) only. Treatments were conducted for 30 days. Rats were bled for a blood test and sacrificed with carbon dioxide gas anesthesia in a closed chamber at the end of the experiment. One part of the liver was sampled for immunohistology. The rest of the liver was rapidly removed and stored at -80°C for RT-PCR and Western blot analysis.
GOT/GPT
The levels of glutamyl oxaloacetic transaminase (GOT) and glutamyl pyruvic transaminase (GPT) in the blood, as hepatic indices of the status of liver function, were measured using the Johnson & Johnson assay Vitros 750 (J&J/Vitros 750). This is a kinetic enzymatic assay in which the rate of formation of the final oxidized leuco dye is monitored at 670 nm. All assays were performed following the procedures described by the manufacturer.
Semiquantitative RT-PCR
The liver was weighed and homogenized in a Trizol reagent (w:v = 1:3; Invitrogen, USA) using a motorized Teflon pestle at 1000 rpm for 2 min on ice to isolate total RNA. Following centrifugation (12,902 g for 15 min at 4°C), the upper phase (clear solution only) was transferred to a new 1.5-ml tube. The supernatant was added to an equal volume of isopropanol and mixed by inverting many times. After incubation at 4°C for 30 min, the tube was centrifuged at 12,902 g for 15 min at 4°C. The supernatant was carefully removed using a pipette. The remaining pellet was washed in 75% ethanol. Following centrifugation (12,902 g for 15 min at 4°C), the supernatant was discarded using a pipette. The pellet was airdried for 5-10 min and resuspended in DEPC-treated water. The optical density (OD) of isolated RNA was measured at 260 nm and 280 nm using a spectrophotometer (Beckman DU640i, USA). The extracted RNA was stored in 100% ethanol at -80°C until the assay. Five micrograms of total RNA was thereafter reverse-transcribed to first-strand cDNA in 20 µl of reaction mixture using a SuperScript™ First-Strand Synthesis System RT-PCR kit (Invitrogen). Sets of PCR primers of selected genes and β-actin were designed with reference to the NCBI database of conserved coding regions (Table 1) . One microliter of cDNA solution and two sets (β-actin and selected gene) of primers were used in 25 µl of PCR reaction samples. The parameters of the β-actin PCR reaction were 25-30 cycles at 95°C for 30 s, 50°C for 30 s and 72°C for 1 min by adding a single cycle of extension at 72°C for 10 min. After 25-30 cycles of amplification and sampling in selected gene vials, ten additional cycles under the same conditions were amplified by performing a single cycle of extension at 72°C for 10 min. PCR products were separated in 12 g/l agarose gel. After ethidium bromide (EtBr, 0.5 µg/ml) staining and photography, the signals were analyzed by phoretix ID standard software (PHORETIX, 61397/28052 MemoHASP1; Feng Jin Biomedical & Instruments Co., Ltd, Taipei, Taiwan), following β-actin (as an internal control) normalization. Data were expressed as the mRNA ratio of selected gene to β-actin following the measurement of the optical density for each cDNA fragment detected. The ratio to control of specific gene presented the comparisons between control and treatments of specific gene after β-actin (as an internal control) normalization. Validation of semiquantitative RT-PCR assays, the amplified cycle numbers of PCR were determined by checking the linear intensity of amplified product in various cycles, and the ratio of two set of primers for selected gene and β-actin used in one reaction was measured in the same way. In the meantime, inserted selected gene plasmid as a template was used to generate a standard curve for the semiquantitative quantization and comparison of a selected gene.
Sequence analysis
The selected PCR amplified product was cloned into plasmid following a previously described cloning procedure to verify the nucleotide sequence. Plasmid DNA of the recombinant colonies was isolated and purified, using a High-Speed Plasmid Mini Kit (Geneaid, Taiwan). Fifty vectors were sequenced simultaneously, from the 5′-end using a Dye Terminator Cycle Sequence FS Ready Kit and a T7 primer from Applied Biosystems (Applied Biosystems ABI 377 sequencer). Sequence files were processed electronically to remove vector sequences, and were then analyzed using an automatic BLAST algorithm to screen the public nucleotide databases.
Western blotting
The liver was homogenized in a homogenization solution (137 mmol/l NaCl, 1 mmol/l CaCl 2 , 1 mmol/l MgCl 2 , Table 1 . Primer sequence and expected lengths of fragments in RT-PCR analysis of rat liver selected genes and β-actin
Gene
Primer sequence Expected lengths of fragments (bp) Table 2 . Following incubation using a secondary antibody (alkaline phosphatase-conjugated goat anti-rabbit/mouse and rabbit anti-goat antibody, 1:4000, Zymed, San Francisco, CA, USA), the protein bands were visualized by ECL autoradiography. The results were quantified using Phoretix 1D Full Version 1.00 and following β-actin (as an internal control) normalization. Data presentation and comparison were the same as mRNA.
Immunohistochemistry
Fresh tissues were carefully embedded in OCT (Optimal Cutting Temperature, 4583, Tissue-Tek, SAKURA) in a plastic mold, without air bubbles surrounding the tissue. The mold was then placed over liquid nitrogen until 70-80% of it turned white and was placed on dry ice. Before sectioning, the frozen block was equilibrated in the cryostat chamber for about 5 min. Sections, 10 µm thick, were mounted on glass slides and dried at room temperature for at least 30 min. After washing twice in PBS, the tissue slide was incubated with 30 ml/l H 2 O 2 for 10 min to reduce the amount of endogenous peroxidase.
The slide was blocked with 70-100 g/l BSA for 20 min after washing. The primary antibodies (diluted in 0.05 mol/l Tris-saline, pH 7.4, 250 ml/l serum), presented in Table 2 , were added directly to the sections and incubated overnight at 4°C. The antibodies were removed and the tissue slide was washed three times in PBS buffer, for 10 min each time, at room temperature. The secondary antibody, diluted in Tris-saline/25 ml/l serum was added and incubated for an additional 45 min at room temperature. After washing, an ABC (avidin and biotinylated horseradish peroxidase macromolecular complex, PK-6105, VECTOR) reagent was added for 30 min of incubation. Methyl green was counterstained for less than 5 min after washing. The slide was sequentially fixed with 700, 850, 950 and 1000 ml/l ethanol and xylene. Afterwards, the slide was washed in deionized water for 5 min and left on a bench to air dry. The stained slide was mounted using VectaMount™, P0505, (VEC-TOR, CA, USA) and microscopic examinations were performed.
Sirius red staining (collagen)
The tissue slide was stained with Weigert's hematoxylin for the nuclei of cells before Sirius red staining. After a 10 min wash, the slide was incubated with Pico Sirius red at room temperature for 1 h. It was then washed twice with acidified water and dehydrated with absolute ethanol. Thereafter, the tissue slide was washed in xylene and fixed in a permanent mounting medium (VECTOR).
Statistical analysis
All data are presented as mean ± SE. Variations among the groups were determined by one-way analysis of variance (ANOVA) using Statistica 6.0 (StarSoft, Inc., Tulsa, USA). The mean was compared with control values using the least significant difference test. *P values < 0.05 and **P values < 0.01 were regarded as the significant level of difference among treatments. 
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RESULTS
Rats post-treated with LPS (5 mg/kg body weight) one month after TAA-injury all died. Therefore, the following experiments were focused on the LPS-pretreatment.
Morphology and GOT/GPT
A morphological comparison with the control rats showed granules on the surface of TAA-injured liver (Fig. 1A) . The GOT/GPT values of TAA-injured rats exceeded (P < 0.05) those of the control rats (Fig. 1B) .
LPS pretreatment reduced the number of granules and lowered GOT (P < 0.05) compared to those of TAAinjured rats (Fig. 1B) but did not alter GPT. Elevated plasma GPT (ALT) activity is more selective for hepatocellular damage than plasma GOT (AST) activity.
Collagen
Following histological section and Sirius red staining, collagen was expressed more densely and was more scattered on the TAA-injured liver of rats. The LPS-pretreated group had less collagen ( Fig. 2A) . Following semiquantitative 180 Chen, Fan, Weng RT-PCR, the expressed levels of collagen 1 (2.5-fold; P < 0.01; Fig. 2B ) and collagen 3 (1.8-fold; P < 0.05; Fig. 2C ) mRNAs in the liver of TAA-injured rats exceeded those of control rats. The expressed levels of collagen 3 mRNA, but not collagen 1 mRNA, were lower (P < 0.05) in the liver of LPS-pretreated rats than that of TAA-injured rats (Fig. 2C ).
Cytochrome P450 (CYP)
According to Western blot analysis of CYP1A1, CYP2A and CYP reductase, the CYP1A1 protein content of liver in TAA-injured rats exceeded (P < 0.05) that in control rats (Fig. 3A) . The CYP1A1 protein content of liver in LPS-pretreated rats did not show significant difference from that in TAA-injured rats (Fig. 3A) . The CYP2A (P < 0.05) and CYP reductase (P < 0.01) protein contents in the liver of TAA-injured rats were lower than those in control rats (Fig. 3B) . In LPS-pretreated rats, CYP2A
protein levels in the liver did not differ from those in TAA-injured rats (Fig. 3B) but the CYP reductase protein level in the liver exceeded (P < 0.05) that in TAAinjured rats (Fig. 3C) . The three groups did not exhibit difference according to CYP1A1, CYP2A and CYP reductase staining of liver frozen sections (Fig. 3D-F) . The data concerning the CYP2A and CYP reductase staining of liver frozen sections were associated with the results of Western blot (Fig. 3B, 3D and 3E, respectively).
TGFβ1/TGFβRI/TGFβRII/TGFβRIII/Smad2
Following semiquantitative RT-PCR, TGFβ1 mRNA in the liver of TAA-injured rats significantly exceeded (P < 0.05) that of the control rats (Fig. 4A) . The levels of TGFβ1 mRNA (P < 0.05) in the liver of LPS-pretreated rats were lower than in the liver of TAA-injured rats (Fig. 4A) . TGFβRI mRNA of liver in LPS-pretreated Fig. 2 . Levels of (A) collagen (immunostaining), (B) collagen 1 and (C) collagen 3 mRNA expressions (semiquantitative PCR) in rat liver following various treatments. *P values < 0.05 and **P values < 0.01 were regarded as significant. Immunocytochemistry of collagen (arrows) stained using Sirius red. Magnification x200. The expression levels of collagen 1 and collagen 3 were measured by semiquantitative PCR with β-actin normalization. rats was higher (P < 0.05) than that of TAA-injured rats but the protein level was not different (Fig. 4B) . The expressed levels of TGFβRII and TGFβRIII mRNAs in the liver of TAA-injured rats were lower (P < 0.05) than those in control rats (Fig. 5A,C) but the mRNA and protein levels of TGFβRI did not differ from those of the control rats (Fig. 4C) . The expressed levels of TGFβRII and TGFβRIII mRNAs did not differ between TAA-injured and LPS-pretreated rats. According to the TGFβRI and TGFβRII staining of liver frozen section, the TGFβRI and TGFβRII of the TAA group were denser (Figs 4D and 5E). This phenomenon was revealed only in the TGFβRII staining of LPS-pretreated rats (Fig. 5B) . Among the treated groups, the expressions of Smad2 mRNA in liver showed a striking increase in the LPS-pretreated group and an increase in the TAA group (Fig. 5D) . 
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Leptin/leptin receptor/Jak2/Stat3
Western blot analysis indicated that the leptin content of liver in TAA-injured rats exceeded (P < 0.05) that in control rats (Fig. 6A) . LPS-pretreated reduced the leptin level below that of TAA-injured rats (Fig. 6A) . According to the leptin staining of the liver frozen section, the TAA group had a denser leptin (Fig. 6F) than 184 Chen, Fan, Weng those in the control and the LPS-pretreated groups. The leptin receptor mRNA of TAA group had lower levels than that of the control group. Compared to the TAAinjured group, LPS-pretreated rats had higher levels but LPS-pretreated and control groups did not show significant differences (Fig. 6B) . The protein levels of leptin receptor in the liver of TAA-injured and LPS-pretreated rats were lower (P < 0.01) than that of the control rats, but no difference existed between the former two groups (Fig. 6C) . The leptin receptor staining data revealed that the leptin receptor expressed in the membrane of the cell did not vary among the three treatments (Fig. 6G) . The expressions of Jak2 and Stat3 mRNA did not vary among the three treated groups according to semiquantitative RT-PCR analysis (Fig. 6D ,E) but LPS-pretreated rats had higher Jak2 mRNA compared with the control and TAA-injured rats.
DISCUSSION
These experimental results demonstrated that TAA caused liver fibrosis, with elevated GOT/GPT levels in blood, increases in collagen 1 and collagen 3 mRNA levels, and high expressions of TGFβ1 and leptin. When chronically injured with TAA (200 mg/kg body weight, 3 times/week), rats exhibit liver fibrosis and further cirrhosis. 30 In the present work, rats treated ten times with TAA (200 mg/kg body weight) suffered liver injury, including high GOT/GPT levels, and collagen 1 and collagen 3 mRNA levels that are consistent with those previously reported. 31 Additionally, the increases in TGFβ1 and leptin mRNA expression in TAA-treated rats caused liver injury, as described in a previous investigation. 28 Exposure to a sublethal dose of LPS renders animals tolerant to a lethal dose of LPS, and protects against the toxicity of some chemicals. 7 In this work, LPS pretreatment inhibited the expression of collagen 3, TGFβ1 mRNA and leptin protein, suggesting that LPS-priming mitigates TAA-induced liver fibrosis by reducing TGFβ1 and leptin levels.
CYP1A1 was increased in the liver of TAA-injured rats while CYP2A and CYP reductase levels dropped in the present study. One report reveals that CYP2A5 is more strongly expressed in TAA-treated rats (25 mg/kg body weight). 32 This difference may be caused by the time course and dose of TAA-treatment or the chemical inducers used. Polycyclic aromatic hydrocarbons induce CYP1A enzymes, phenobarbital induces CYP2B, ethanol induces CYP2E, and TAA (25 mg/kg body weight) induces CYP2A5. 32 Moreover, inflammation of the liver, as caused by hepatitis B virus or liver fluke induce CYP2A5. 33, 34 LPS pretreatment inhibits hepatic cytochrome P450 enzymes and protects against the hepatotoxicity of acetaminophen (400 mg/kg) and CCl 4 (30 mg/kg) during short-term injury. This protective effect of LPS seems to be mediated by the release of cytokines such as IL-1α which, in turn, inhibits the cytochrome P450 that is responsible for activating CCl 4 to reactive metabolites. 5 When rats were administered a combination of hepatocyte growth factor (HGF, 10 mg/kg) and LPS (5 mg/kg), LPS increases HGF that promotes replication in the lung, thyroid, spleen and colon. However, LPS can increase the expression of c-met (HGF receptor) in the thyroid, spleen and intestine. 35 Endotoxin tolerance and subsequent survival are also associated with an increase in anti-inflammatory (IL-4 and IL-10) mRNA expression. LPS protects the liver by preventing hepatic mononuclear cellular infiltration, reducing the production of toxic pro-inflammatory cytokines, and inducing the production of endogenous anti-inflammatory cytokines. 36 In this work, LPS pretreatment failed to change CYP1A1 and CYP2A levels but increased CYP reductase. Previously, flavin-containing mono-oxygenases have been implicated in the metabolism of TAA to its toxic metabolites. 37 Moreover, lowered activities of enzymes related to the cytochrome P450 mono-oxygenase systems (NADPH cytochrome P450 reductase and NADH cytochrome b 5 reductase) reveal that liver cells are not protected against the peroxidative stress produced by chronic administration of TAA. 38 NADPH-cytochrome P450 reductase is an essential component of the microsomal cytochrome P450 mixed function oxidase system, regulating electron transfer from NADPH to cytochrome P450. 39 It is likely to reduce oxidative stress and to ameliorate liver injury induced by LPS-pretreatment.
TGFβs are multifunctional growth factors that can modulate cell growth, differentiation, angiogenesis, inflammatory reactions and immune reactions. TGFβ1 is an important regulator under both normal and pathological conditions in the liver. 40 TGFβ1 which is produced in non-parenchymal cells, such as HSCs and KCs, 41 can also suppress hepatocellular DNA synthesis both in vitro and in vivo. 42, 43 Additionally, TGF-β1 promotes the synthesis and deposition of ECM proteins such as fibronectin 6, 40, 44 and collagen 26 by HSCs and is closely related to the progression of hepatic fibrosis. Three main types of TGFβ binding proteins (receptors) are known to be distributed extensively in most TGFβ-responsive cells. They are designated as TGF-β type I (TGFβRI), type II (TGFβRII) and type III (or β-glycan; TGFβRIII) receptors. 45, 46 The increase in TGFβ1 following CCl 4 injury, and the down-regulation of TGFβRI and TGFβRII in hepatocytes occurs at 48 h, but not at 72 h, while the TGFβRIII content in HSCs fails to change and the signaling of TGFβ1 proceeds. 40 Moreover, the expression of TGFβRII falls during chronic hepatitis C. 47 In this work, the decreases in the expressions of TGFβRII and TGFβRIII in the liver of TAA-injured rats were consistent with those reported elsewhere; 31, 48 nevertheless, the TGFβRI content did not decline in the present study. The recent identification of the SMAD family of signal transducer proteins elucidates the mechanisms by which TGFβ signals from the cell membrane to the nucleus. In response to TGFβ, TGFβRI phosphorylated Smad2 and Smad3, and then the ligand-activated Smad2 and Smad3 may translocate into the nucleus to regulate transcription. 49 In this work, LPS pretreatment failed to up-regulate TGFβRII expression, even when TGFβ1 decreased. Conversely, the down-regulation of TGFβRII and TGFβRIII may be caused by the combined effects of TAA and LPS. In addition, the expressions of TGFβRI and TGFβRIII in both TAA and LPS-pretreated groups did not differ significantly. In contrast, Smad2 mRNA was increased in both TAA and LPS-pretreated groups. The increased tendency of Smad2 mRNA in LPS-pretreated group was higher than that of the TAA group. Moreover, the pretreatment of LPS did not affect TGFβRs during liver injury caused by TAA. However, the mechanism of the down-regulation of TGFβ1 following LPS pretreatment must be examined in the future.
One investigation has reported that leptin is expressed in the liver of TAA-injured rats and promotes liver fibrosis. 28, 30 The leptin receptor (Ob-R), isolated by expression cloning, is encoded by the diabetes (db) gene, alternate splicing of which forms six leptin receptor (Ob-Ra-f) isoforms. 50, 51 The leptin receptor is a member of the class I cytokine receptor superfamily. Like other family members, leptin receptor activation stimulates Stat1, Stat3 and Stat5 tyrosine phosphorylation in vitro and Stat3 tyrosine phosphorylation in vivo. 52 The leptin content is increased in phenobarbital-and CCl 4 -induced liver but the leptin receptor is not altered. 53 In this work, the leptin receptor mRNA and protein were down-regulated in the TAA group, and associated with an increase in leptin content. However, the decline in the leptin content caused by LPS pretreatment augmented the leptin receptor mRNA and not existing in protein level. This discrepancy between TAA and LPS-pretreated groups may be the tolerance of LPS in stellate cells that secret leptin in liver, which was lower than that in the TAA group, causing the up-regulation of the leptin receptor mRNA in the liver of LPS-pretreated rats. The tolerance of the stellate cell was induced by LPS pretreatment, and inhibited the expression of leptin following treatment with TAA. A previous report has demonstrated that Stat3 can also be activated by leptin. 54 One more study shows that Stat3 activation does not require de novo protein synthesis, indicating that the cytoplasm contains a reserve pool of Stat3. 55 This interpretation is consistent with our work, that there was no difference in Stat3 mRNA expression in both TAA and LPS-pretreated groups. Furthermore, Stat3 is hyperphosphorylated when cell cycle progression is inhibited in the liver. 56 Thus, whether LPS-pretreated caused the hyperphosphorylation of Stat3 in the present study remains to be explored.
CONCLUSIONS
Taken together, LPS pre-treatment modulates TAAinduced the liver injury, whereas LPS post-treatment deteriorates the toxicity of TAA. This implies the causation of LPS infection for the liver injured animal or human. Moreover, endotoxin tolerance of LPS may provide alternative considerations for generating significant compounds to prevent chemical liver injury.
